Coca-Cola HBC (CCHGY)
(Delayed Data from OTC)
$31.44 USD
-0.12 (-0.36%)
Updated Apr 25, 2024 09:32 AM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CCHGY 31.44 -0.12(-0.36%)
Will CCHGY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CCHGY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CCHGY
Coca-Cola HBC (CCHGY) Upgraded to Buy: What Does It Mean for the Stock?
Should Value Investors Buy Coca-Cola HBC (CCHGY) Stock?
CCHGY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is BRC INC (BRCC) Outperforming Other Consumer Staples Stocks This Year?
Has Coca-Cola HBC (CCHGY) Outpaced Other Consumer Staples Stocks This Year?
Are Investors Undervaluing Coca-Cola HBC (CCHGY) Right Now?
Other News for CCHGY
UK earnings, trading statements calendar - next 21 days
UK earnings, trading statements calendar - next 21 days
UK earnings, trading statements calendar - next 21 days
Coca-Cola HBC: Cheap At Less Than 7 Times Ebitda
LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'